Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Panobinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 12/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 5/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 4/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 3/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 3/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 3/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 8/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | FOXO1 | Q12778 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panobinostat SCHEMBL22773814 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL183197 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL436875 | 0.99 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL20165843 | 0.99 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL30235437 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL29358399 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315056 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315067 | 0.93 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL10036755 | 0.93 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316088 | 0.93 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2147 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-01-20 | — | — | US | claimed |
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENT AB (SE) | 2023-11-16 | — | — | US | claimed |
| US-20230070370-A1 | PROCESS FOR THE PREPARATION OF PANOBINOSTAT | FLAMMA SPA (IT) | 2023-03-09 | — | — | US | claimed |
| US-11554123-B2 | Compositions and methods for reactivating latent HIV-1 infections | SAINT JOSEPH'S UNIVERSITY (US) | 2023-01-17 | — | — | US | claimed |
| US-20210340218-A1 | MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS | LA JOLLA INST ALLERGY & IMMUNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | claimed |
| US-20200179381-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENTIFIC AB (SE) | 2020-06-11 | — | — | US | claimed |
| EP-3662903-A2 | COMBINATION THERAPIES | Novartis AG (CH) | 2020-06-10 | — | — | EP | claimed |
| US-20200016168-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | SAINT JOSEPH'S UNIVERSITY | 2020-01-16 | — | — | US | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | SECURA BIO, INC. | 2005-04-21 | — | — | US | claimed |
| WO-2005013958-A1 | HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | claimed |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | claimed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | claimed |
| EP-1456664-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | Novartis AG (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | claimed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | claimed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | claimed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |